Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis

被引：1

作者：

Alexis, Andrew ^{[1
]}

Ardern-Jones, Michael ^{[2
]}

Chovatiya, Raj ^{[3
]}

Flohr, Carsten ^{[4
,5
]}

Irvine, Alan ^{[6
]}

AlMurrawi, Muna ^{[7
]}

Atwater, Amber Reck ^{[8
]}

Ding, Yuxin ^{[8
]}

Qiao, Meihua ^{[9
]}

Pierce, Evangeline ^{[8
]}

Pau-Charles, Ignasi ^{[10
]}

Heath, Candrice ^{[11
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Univ Southampton, Southampton, Hants, England

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[4] Kings Coll London, St Johns Inst Dermatol, London, England

[5] Guys & St Thomas NHS Fdn Trust, London, England

[6] Trinity Coll Dublin, Dublin, Ireland

[7] Dr Muna AlMurrawi Med Ctr DMA, Abu Dhabi, U Arab Emirates

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] Tigermed, Somerset, NJ USA

[10] Almirall SA, Barcelona, Spain

[11] Temple Univ, Lewis Katz Sch Med, Dept Dermatol, Philadelphia, PA USA

来源：

关键词：

atopic dermatitis; lebrikizumab; race; ethnicity;

D O I：

10.1093/bjd/ljad498.024

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

517

引用

页码：II20 / II21

页数：2